San Francisco Marriott Marquis, San Francisco, CA, United States of America
The Symposium, celebrating its 10th year, will allow attendees to revisit the challenges and triumphs of the past decade, while examining the future direction of the field through ground-breaking scientific presentations paired with integrated educational lectures and discussions.
This year’s Meeting will feature the following key studies:
Results from a randomized, double-blind, phase III trial evaluating enzalutamide in men with metastatic castration-resistant prostate cancer who had not previously received chemotherapy (Abstract #LBA1^)
Findings from a Scandinavian Prostate Cancer Group VII trial analyzing 10- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (Abstract #4)
Renal Cell Cancers
A retrospective study investigating the impact of a common hypertension drug on survival rates of patients with metastatic renal cell cancer (Abstract #437)
GU Clinical Trials
A literature review on the early termination of genitourinary cancer clinical trials (Abstract #288)
All clinicians and researchers interested in cutting-edge science and innovation related to the treatment of GU cancers should plan to attend and celebrate ten years of progress.